All In MedTech

Device Trial Radar · NCT07943143

Histotripsy for Renal Cell Carcinoma

Histotripsy for Renal Cell Carcinoma: a Pilot Study for a Novel Focused Therapy With an Unmet Need

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

15

Planned (sponsor's estimate)

Start

Oct 13, 2026

Primary completion

Oct 30, 2028

Study completion Oct 30, 2029

Sponsor

Lead sponsor
The University of Hong KongAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Gleneagles Hospital
First posted
Nov 17, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The project will be a pilot study in localised or metastatic renal cell carcinoma, assessing safety, local control, and exploratory immune endpoints. Outcomes from this work will inform rational combinations with targeted agents and immune checkpoint blockade and may define a new, image-guided, non-invasive modality for renal cell carcinoma. If successful, histotripsy could become a new non-thermal, local therapy for renal cell carcinoma with dual benefits of debulking and immune activation achieving strong clinical and scientific impact.

Conditions

  • Localised or Metastatic Renal Cell Carcinoma

Interventions

  • HistoSonics® Edison System (US)Device

    Patients with be admitted to Gleneages Hospital for histotripsy procedure. Pre-produce anaestetic assessment will occur and patients will be treated under general anasestetic with jet ventilation. Patient will be positioned in the left or right lateral position and a water tank will be placed over the patient's loin area. The histotripsy ultrasound and treatment head will be placed inside the water tank and image-guided histotripsy ablation of the kidney tumor will be performed. The expected length of hospital stay is 1 day after operation. Patient will undergo follow up with regular imaging up to 6 months.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess efficacyTime frame: 90 days post procedure
  2. To assess treatment safetyTime frame: At 30 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Gleneagles Hospital Hong Kong

    Hong Kong, Hong Kong · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.